Moderna Stock Jumps 6% as Investors Compare Its Vaccine Momentum With Pfizer and Novavax
Moderna Stock Jumps 6% as Investors Compare Its Vaccine Momentum With Pfizer and Novavax
Moderna stock moved sharply higher on Monday, rising about 6% in morning trading as renewed vaccine interest, stronger-than-expected quarterly revenue, and biotech momentum pushed the company ahead of Pfizer and Novavax.
Shares of Moderna traded near $57.52 after closing the previous session at $54.35, according to market data cited by 24/7 Wall St. The move made Moderna one of the stronger vaccine-related names of the day, while Pfizer gained roughly 2% and Novavax remained almost flat. The report also noted that Moderna has risen about 95% year to date, compared with around 50% for Novavax and about 5% for Pfizer.
Why Moderna Stock Rose
The latest rally appears to be driven by a mix of market sentiment and improving fundamentals. Investor attention returned to vaccine makers after reports of a recent cruise ship outbreak renewed discussion around Hantavirus. Moderna has early-stage research tied to an mRNA-based Hantavirus vaccine, which helped attract retail traders and momentum-focused investors.
However, the Hantavirus angle should be viewed carefully. While headlines can move biotech stocks quickly, early vaccine research does not usually create near-term revenue. Hantavirus outbreaks have also historically been limited in scale, meaning investors should not assume a large commercial opportunity without stronger evidence.
Moderna’s Earnings Helped Support the Rally
Beyond the headline-driven buying, Moderna’s recent financial results gave investors another reason to pay attention. The company reported first-quarter 2026 revenue of $389 million, beating analyst expectations of about $236 million. International product sales were especially important, contributing $311 million, compared with $78 million from the United States.
Management also reaffirmed its full-year outlook, including expectations for up to 10% revenue growth and a year-end cash position between $4.5 billion and $5 billion. That cash cushion matters because Moderna is still investing heavily in new products beyond COVID-19 vaccines.
How Moderna Compares With Pfizer
Pfizer is a much larger and more diversified pharmaceutical company. Its vaccine business is important, but it is only one part of a broad portfolio that includes medicines across several categories. Because of that, Pfizer stock is usually less sensitive to one vaccine headline.
For income-focused investors, Pfizer may still look attractive because of its dividend profile. But for traders looking for faster vaccine-related momentum, Moderna has recently been the more responsive stock.
How Moderna Compares With Novavax
Novavax is smaller than both Moderna and Pfizer, which means its stock can move sharply when vaccine news changes investor sentiment. The company recently reported a $30 million upfront payment connected to a Pfizer Matrix-M adjuvant license, with the possibility of up to $500 million in milestone payments.
Still, Novavax has experienced several boom-and-bust cycles since the COVID vaccine era. That makes it a higher-risk, higher-volatility name compared with Pfizer and, in some ways, even Moderna.
What Investors Are Watching Next
One major upcoming catalyst for Moderna is the August 5 PDUFA date for its seasonal flu vaccine candidate, mRNA-1010. If approved, it would become Moderna’s fifth commercial product and could help the company move further beyond its COVID-19 vaccine business.
Investors are also watching Moderna’s broader pipeline, including programs in flu, RSV, oncology, rare diseases, norovirus, and melanoma. Success in these areas could strengthen the long-term case for Moderna’s mRNA platform.
Risks Behind the Moderna Rally
Despite the strong move, investors should remain cautious. Moderna’s COVID-era revenue has declined from its peak, and the company continues to face large research and development costs. The latest quarter also included a major non-recurring litigation charge, which affected profitability.
The biggest risk is that the current rally may be partly sentiment-driven. A single outbreak headline does not automatically mean strong future vaccine demand. Biotech stocks can rise quickly, but they can also fall quickly when excitement fades.
Bottom Line
Moderna is currently outperforming Pfizer and Novavax both on the day and year to date. Its strong first-quarter revenue beat, international sales growth, and vaccine pipeline have helped rebuild investor confidence.
Still, Moderna remains a volatile biotech stock. The bullish case depends on successful product approvals and pipeline progress, while the bearish case focuses on falling COVID-related revenue, continuing losses, and the risk that recent enthusiasm may cool.
For now, Moderna is the clear momentum leader among these three vaccine stocks, but investors should watch upcoming regulatory decisions and earnings updates before assuming the rally can continue.
#SlimScan #GrowthStocks #CANSLIM